(“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced a first closing of $27 million (circa £22 million) in its Series E ...

Owlstone Medical has secured the first closing of its Series E financing round, securing $27m (approximately £22m) to advance ...

Patients with a common aggressive type of bladder cancer could get correct treatment significantly quicker as new research ...

The liver cirrhosis treatment market is poised for significant growth, driven by the rising global prevalence of liver diseases, particularly NAFLD, fueled by lifestyle factors like obesity, alcohol ...

Marissa Antonio was 39-years-old when she was diagnosed with a 19cm liver tumour - and the nurse went on to issue a warning ...